Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flopropione for prevention of cisplatin-induced nephrotoxicity
jRCTs041220021Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of flopropione in cancer and Cisplatin-Induced Nephropathy (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Occurrence of adverse events. Started Jul 2024; status: completed.
02
Drugs
flopropione
03
Conditions
cancerCisplatin-Induced Nephropathy
Beyond the preview
Go deeper on jRCTs041220021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220021.